Analysts Turned Bullish on These 10 Stocks on Tuesday

Wall Street is trading on what the Federal Reserve does next, even as analysts keep changing their ratings. The Fed held its key rate steady at its October 27 to 28 meeting, after raising it in September for the first time in three years.

Minutes released on November 18 showed that nearly all officials expect a quarter-point increase in December, and two raised the idea of a half-point move. Wall Street puts the odds of a December hike near 95%, according to the CME Group’s FedWatch tool.

The jump in expectations began on November 10, when a hotter-than-expected October inflation report sent the 2-year Treasury yield up more than 18 basis points, its biggest one-day rise since April 2025, Reuters reported.

Why the Fed May Not Be Done Raising Rates

Fed Governor Christopher Waller backs the larger move. He said inflation is “headed in the wrong direction and it’s spreading out,” and he put core inflation at about a 3.5% annual rate over the past three months, against the Fed’s 2% target. Readers following analysts’ favorite growth names can find more in our ranking of aggressive growth picks from Wall Street analysts.

New York Fed President John Williams disagrees and does not think the situation calls for dramatic action. St. Louis Fed President Alberto Musalem has said the economy will likely need several rate increases before spring 2027, and San Francisco Fed President Mary Daly leans toward more hikes because she worries that companies are passing higher costs on to consumers.

Treasury Yields Back Above 5% Draw Investor Attention

The 10-year Treasury yield touched 5.36% on October 7, its highest level in regular trading since 2002, and it was on pace on November 17 for its 27th close above 5% this year, Bloomberg reported. All of 2007 had 29 such closes. Analysts are still finding value at these levels, as our list of affordable stocks to buy according to Wall Street analysts shows.

JPMorgan Asset Management portfolio manager Priya Misra said yields above 5% reflect a “risk premium due to uncertainty about the Fed.” Dan Carter of Fort Washington Investment Advisors said fixed income offers better risk and reward than it has in some time, and that the stock rally since 2023 may push many portfolios to rebalance toward bonds. The pressure is also showing up in housing: 30-year mortgage rates have stayed above 7% since mid-September, and Ian Lyngen of BMO Capital Markets said the effect on real estate has been to freeze activity.

Analysts Turned Bullish on These 10 Stocks on Tuesday

Our Methodology

To compile this list, we reviewed analyst rating upgrades and price target increases announced on Tuesday, November 17, 2026. We selected 10 stocks that are listed in the U.S. and had an analyst call that day, and ranked them in ascending order of their average upside potential. Upside is based on analysts’ average price target compared with each stock’s share price, as of November 18.

At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

Analysts Turned Bullish on These 10 Stocks on Tuesday

10. Medtronic (NYSE:MDT)

Average Upside Potential: 5%

Piper Sandler analyst Matt O’Brien upgraded Medtronic to Overweight from Neutral on November 17 and raised his price target to $120 from $85. He expects growth drivers to push revenue above consensus, with cardiac ablation leading in the near term and an investor meeting set for December 11.

Medtronic makes device-based therapies for heart, brain and surgical care. In the first quarter of fiscal 2027, sales of its Cardiac Ablation Solutions products grew 88%, the Cardiovascular portfolio grew 18.9%, and the company raised its fiscal 2027 organic revenue growth guidance by 50 basis points. Non-GAAP earnings per share also rose from a year earlier, and the quarter included an extra fiscal week that added about $570 million in revenue. On November 16, Medtronic announced plans to acquire Contego Medical, and on November 17 it said the FDA had cleared its Hugo robotic system for general surgery.

Medtronic is expected to report its next quarterly results on November 24, and analysts expect earnings of $1.33 per share. We examined how Medtronic’s modest valuation lines up with its improving growth outlook in a separate piece.

9. United Natural Foods (NYSE:UNFI)

Average Upside Potential: 6%

Goldman Sachs analyst Leah Jordan upgraded United Natural Foods to Buy from Neutral on November 17 and raised her price target to $60 from $49. She pointed to the company’s outsized exposure to the higher-growth natural and organic category.

United Natural Foods distributes natural, organic and specialty foods to grocery stores and other retailers. Profit has grown faster than sales. In the fourth quarter of fiscal 2026, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose 48.3% while net sales fell from a year earlier. That leaves the bull case resting on profit growth continuing without much help from the top line. For fiscal 2027, the company guided to adjusted EBITDA above the $701 million it earned in fiscal 2026. It also generated $323 million of free cash flow in fiscal 2026 and announced a new share buyback.

United Natural Foods is expected to report its next quarterly results on December 8, and analysts expect earnings of $0.66 per share. Our earlier coverage of how the distributor called a bottom and guided for growth again has more on that outlook.

8. Zimmer Biomet (NYSE:ZBH)

Average Upside Potential: 13%

Wells Fargo analyst Larry Biegelsen upgraded Zimmer Biomet to Overweight from Equal Weight on November 17 and set a price target of $123, up from $113. He pointed to the launch of the Monogram robot in the first half of 2027 as a fix for knees, the company’s weak spot.

Zimmer Biomet makes artificial knees, hips and other orthopedic implants, along with sports medicine, trauma and spine products. Knees are the line holding the numbers back. Their sales fell 3.1% in the third quarter of 2026, while hips grew 6.0%, and the business covering sports medicine, extremities and trauma also grew.

The company reported those results on November 4. Net sales rose in constant currency, which leaves out the effect of exchange rates, and the company raised its 2026 adjusted earnings per share guidance to a range of $8.50 to $8.60, along with its outlook for reported revenue growth. Chief Executive Officer Ivan Tornos said the company was “very pleased with our solid third quarter results.” Wells Fargo’s upgrade rests on the view that the rest of the business can keep growing while knees recover.

7. Centene (NYSE:CNC)

Average Upside Potential: 13%

Bernstein raised its price target on Centene to $90 from $79 on November 17 and kept its Outperform rating. The firm pointed to a recovery in the company’s Medicaid business after its results for the third quarter of 2026, which Centene reported on October 27.

Centene runs government-sponsored health plans, including Medicaid, Medicare and commercial coverage. In the third quarter of 2026, it earned adjusted earnings of $0.58 per share, and it raised its 2026 adjusted earnings guidance to above $5.20. On a GAAP basis, it reported a loss of $0.14 per share. It also said it had cut debt by $1.1 billion since June 30.

A new risk arrived on November 18, when the Centers for Medicare & Medicaid Services proposed a rule that would tighten oversight of Medicare, Medicaid, the Children’s Health Insurance Program and the health insurance marketplace, with more audits of insurers and a way for the agency to recover improper payments. Public comment on the proposal is open until January 19, 2027. We covered the turnaround playbook Centene handed to a new technology chief in an earlier piece.

6. TIM (NYSE:TIMB)

Average Upside Potential: 15%

Itau BBA analyst Maria Infantozzi upgraded TIM to Outperform from Market Perform on November 17 and raised her price target to R$25 from R$23, citing downside protection and the potential for higher payouts to shareholders.

TIM provides mobile, internet and ultra-broadband services in Brazil, including fixed broadband under the TIM Ultrafibra name. In the third quarter of 2026, net revenue rose 5.3% and normalized EBITDA, a profit measure that leaves out one-time items, also rose. Normalized net income fell 7.8%, which is the weak spot in the report. Reported net income, before those adjustments, was lower still. Itau BBA’s call came after TIM reported on November 9 and filed the results with the SEC on a Form 6-K. Reported amounts here are in Brazilian reais. Operating free cash flow rose, however, and that cash is what funds the payouts Itau BBA expects.

TIM guided to shareholder remuneration of R$5.3 billion to R$5.5 billion for 2026, and its net debt relative to normalized EBITDA was lower than in June, which leaves room for payouts. The board approved a new buyback program on August 19.

5. Nucor (NYSE:NUE)

Average Upside Potential: 23%

Morgan Stanley upgraded Nucor to Overweight from Equalweight on November 17 and raised its price target to $310 from $300, pointing to lower capital spending.

Nucor makes steel and steel products through three segments: steel mills, steel products and raw materials. In the third quarter of 2026, it earned $5.80 per diluted share on net sales of $11.25 billion, up from $2.63 per share a year earlier, and steel mill shipments reached 7,231 thousand tons, up from 6,428 thousand tons a year earlier. Over the first nine months of 2026, free cash flow came to $2.66 billion, and the company returned cash to shareholders, much of it through share repurchases.

Nucor’s new sheet mill in West Virginia had its first heat in September. In Morgan Stanley’s view, lower capital spending leaves more cash for buybacks and dividends. Nucor reported those results on October 26 and said it expects fourth-quarter earnings to be in line with or modestly higher than the third quarter. Our piece on Nucor’s strong shipments and the questions around its third-quarter guidance covers the debate over that outlook.

4. Humana (NYSE:HUM)

Average Upside Potential: 32%

Bernstein raised its price target on Humana to $515 from $425 on November 17 and kept its Outperform rating. The firm said stable medical use and industry pricing discipline support a recovery in Medicare Advantage margins.

Humana sells Medicare Advantage and other health insurance plans and runs the CenterWell care business. In the third quarter of 2026, Humana reported GAAP earnings of $1.33 per share but an adjusted loss of $0.70 per share, against adjusted earnings of $3.24 a year earlier, as revenue grew. Humana reported those results on November 6, 2026. It raised its 2026 adjusted earnings guidance to at least $9.50.

On November 18, the Centers for Medicare & Medicaid Services proposed a rule that would tighten oversight of Medicare, Medicaid and the health insurance marketplace, with more audits of insurers and a way for the agency to recover improper payments, and Humana was among the insurers whose shares fell. Public comment on the proposal is open until January 19, 2027. We wrote about how Humana expects most of its members to be in four-star plans before that.

3. M-tron Industries (NYSEAMERICAN:MPTI)

Average Upside Potential: 34%

Freedom Broker analyst Sergey Glinyanov upgraded M-tron Industries to Buy from Hold on November 17 even as he cut his price target to $84 from $88, citing “lower valuation multiples and a higher discount rate.” He still raised his estimates for 2026 through 2028, with the biggest increase in 2028 on missile programs for Raytheon and Lockheed Martin.

M-tron makes frequency and spectrum control products, such as oscillators and filters, for aerospace and defense customers. Revenue in the third quarter of 2026 rose to $15.7 million, and backlog stood at $84.9 million on September 30, up from the end of 2025. M-tron reported those results on November 12, before Freedom Broker moved to Buy.

Glinyanov expects 2027 to be a transition year, with costs for added capacity and new hires weighing on results. He also sees the company’s radar business growing from under $2 million to about $8 million a year. Management cautioned that backlog could dip in the fourth quarter, which Freedom Broker attributed to contract timing rather than weaker demand. Freedom Broker also called the September 30 backlog a record high.

2. Cisco Systems (NASDAQ:CSCO)

Average Upside Potential: 35%

HSBC upgraded Cisco to Buy from Hold on November 17 and raised its price target to $133 from $120, pointing to growth in AI networking.

Cisco designs and sells the networking equipment and software that connect company and cloud data centers. In the first quarter of fiscal 2027, revenue rose 24% from a year earlier, and Chief Executive Officer Chuck Robbins said, “We are in the very early stages of a multi-year networking supercycle.” The company expects $9 billion in AI infrastructure revenue from hyperscalers in fiscal 2027, more than double the total for fiscal 2026. Product revenue grew faster than total revenue in the first quarter, which ended on October 24, 2026.

Robbins, who spoke when the company reported on November 12, also said the quarter brought Cisco’s strongest revenue and earnings per share growth in more than 15 years, and the company raised its fiscal 2027 non-GAAP earnings per share guidance to $5.47 to $5.53. Our analysis of whether Cisco can profit from helping customers spend less on AItakes up the other side of that demand.

1. Praxis Precision Medicines (NASDAQ:PRAX)

Average Upside Potential: 120%

Wells Fargo analyst Ben Burnett upgraded Praxis Precision Medicines to Overweight from Equal Weight on November 17 and raised his price target to $509 from $343. He said the company’s investor day on November 12 had eased his concerns about the endpoint in its ulixacaltamide trial.

Praxis develops treatments for brain disorders such as essential tremor and rare genetic forms of epilepsy. The FDA’s target decision date for relutrigine, which treats two types of developmental and epileptic encephalopathy, is December 27, 2026, and the date for ulixacaltamide, for essential tremor, is January 29, 2027. Chief Executive Officer Marcio Souza said, “We are entering a defining period for Praxis, with two key regulatory milestones ahead.”

The company ended the third quarter of 2026 with about $1.3 billion in cash and investments, which it expects to fund operations into 2028. Its net loss widened to $94.2 million from $73.9 million a year earlier, and the company also expects results from its EMERALD trial in the fourth quarter of 2026. Praxis said the relutrigine team is fully hired and that it expects the ulixacaltamide sales force to be in place in the fourth quarter of 2026.

READ NEXT: Cisco (CSCO): Can Software Renewals Outlast the Networking Upgrade Cycle? and Cisco (CSCO): Can Its Earnings Recovery Turn Into Lasting Cash Growth?

Follow Insider Monkey on Google News.